DRD2 and schizophrenia: A PET study by Girgis et al. in 2016 found that administering 1 mg and 3 mg of cariprazine daily for two weeks to schizophrenia patients led to dopamine D2 receptor occupancies of 45% and 79%, respectively, and D3 receptor occupancies of 76% and 92% [41].